Groupama Asset Managment Has $65.65 Million Stake in Exact Sciences Corporation $EXAS

Groupama Asset Managment reduced its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 0.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,200,000 shares of the medical research company’s stock after selling 10,236 shares during the quarter. Groupama Asset Managment’s holdings in Exact Sciences were worth $65,652,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. CIBC Private Wealth Group LLC raised its stake in Exact Sciences by 47.7% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,333 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 1,399 shares during the period. CIBC Bancorp USA Inc. acquired a new position in shares of Exact Sciences in the third quarter valued at $507,000. Centaurus Financial Inc. increased its holdings in shares of Exact Sciences by 5.0% in the third quarter. Centaurus Financial Inc. now owns 2,517 shares of the medical research company’s stock valued at $138,000 after purchasing an additional 120 shares during the last quarter. Captrust Financial Advisors raised its position in shares of Exact Sciences by 35.1% in the third quarter. Captrust Financial Advisors now owns 30,424 shares of the medical research company’s stock valued at $1,664,000 after purchasing an additional 7,897 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Exact Sciences during the 3rd quarter worth about $164,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $103.75 on Thursday. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $19.80 billion, a P/E ratio of -94.32, a P/E/G ratio of 2.37 and a beta of 1.41. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $104.00. The firm has a 50-day moving average price of $102.96 and a two-hundred day moving average price of $85.05.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter in the prior year, the firm earned ($0.06) EPS. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. Analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on EXAS. Mizuho reaffirmed a “neutral” rating and set a $105.00 target price (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th. William Blair downgraded shares of Exact Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 20th. Citigroup cut Exact Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Finally, Evercore set a $105.00 price target on Exact Sciences and gave the stock an “in-line” rating in a report on Monday, January 5th. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.